Shots: The P-III CAPTAIN study involves assessing of Trelegy Ellipta (FF/UMEC/VI) (100/31.25/25, 100/62.5/25, 200/31.25/25 and 200/62.5/25 mcg) vs Relvar/Breo Ellipta (FF/VI) (100/25 and 200/25 mcg) in 2,436 patients with uncontrolled […]readmore
Tags : CAPTAIN Study